Earnings Call Summary | Accelerate Diagnostics(AXDX.US) Q2 2024 Earnings Conference
Earnings Call Summary | Accelerate Diagnostics(AXDX.US) Q2 2024 Earnings Conference
Net loss for the quarter was approximately $11.6 million, with a net loss per share of $0.50.The following is a summary of the Accelerate Diagnostics, Inc. (AXDX) Q2 2024 Earnings Call Transcript:
以下爲Accelerate Diagnostics（簡稱accelerate diagnostics）2024年第二季度業績會議通話記錄摘要：
Financial Performance:
金融業績：
Accelerate Diagnostics, Inc. reported Q2 2024 net sales of approximately $3 million, compared to $2.9 million in Q2 2023.
Gross margin for Q2 2024 was approximately 23%, a decrease from 27% in Q2 2023, influenced by product mix.
Net loss for the quarter was approximately $11.6 million, with a net loss per share of $0.50.
Accelerate Diagnostics公司報告2024年第二季度淨銷售額約爲300萬美元，相比於2023年第二季度的290萬美元。
2024年第二季度毛利率約爲23％，較2023年第二季度的27％下降，其原因影響了產品組合。
本季度淨虧損約爲1160萬美元，每股淨虧損爲0.50美元。
Business Progress:
業務進展：
Successfully completed preclinical trials with Wave platform, demonstrating a strong performance and readiness for clinical trials.
Advanced Wave platform to clinical trial phase, with system installations at four external sites and necessary Gram-Negative test kits manufactured.
Secured approximately 75% of U.S. customer base in longer-term contracts ahead of the Wave commercial launch.
成功完成Wave平台的臨床前試驗，表現良好，準備好參加臨床試驗。
將Wave平台推進臨床試驗階段，系統在四個外部站點進行安裝，必要的革蘭氏陰性試劑盒已製造完成。
在Wave商業發佈之前，已經與大約75％的美國客戶簽訂了較長期的合同。
Opportunities:
機會：
Expansion into the isolate susceptibility testing market, which is expected to potentially grow existing customer annuities by 3 to 4 times.
Application of holographic imaging technology in other areas of diagnostic testing to further expand the addressable market.
擴展到孤立感受性測試市場，預計可能將現有客戶年金增長3至4倍。
應用全息成像技術在其他診斷測試領域進一步擴大可尋址市場。
Risks:
風險：
Continuing development and commercialization of the Wave system, which involves significant financial expenditure and operational execution.
正在繼續開發和商業化Wave系統，這涉及到重大的財務支出和操作執行。
More details: Accelerate Diagnostics IR
更多詳情請查看Accelerate Diagnostics IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
